Sontra Medical Corporation has recently been granted U.S. Patent No. 7,066,884 entitled, "System, Method, and Device for Non-Invasive Body Fluid Sampling and Analysis" that describes the technology for transdermal continuous glucose monitoring.

"This patent further strengthens the intellectual property portfolio surrounding Sontra's non-invasive diagnostics, and is central in transdermal and continuous glucose monitoring technology," stated Scott Kellogg, Sontra's Vice President of Research and Development.

Sontra Medical Corporation's continuous non-invasive glucose monitoring
technology measures glucose diffusing through ultrasonically permeated skin for twenty- four hours. This technology has significant implications in the critical care setting, as well as in the home glucose testing.

Read more at Sontra Medical Corporation.